• Something wrong with this record ?

Drug-target interaction prediction: A Bayesian ranking approach

L. Peska, K. Buza, J. Koller,

. 2017 ; 152 (-) : 15-21. [pub] 20170908

Language English Country Ireland

Document type Journal Article

BACKGROUND AND OBJECTIVE: In silico prediction of drug-target interactions (DTI) could provide valuable information and speed-up the process of drug repositioning - finding novel usage for existing drugs. In our work, we focus on machine learning algorithms supporting drug-centric repositioning approach, which aims to find novel usage for existing or abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects the needs of drug-centric repositioning research better than conventional drug-target prediction approaches. METHODS: We propose Bayesian Ranking Prediction of Drug-Target Interactions (BRDTI). The method is based on Bayesian Personalized Ranking matrix factorization (BPR) which has been shown to be an excellent approach for various preference learning tasks, however, it has not been used for DTI prediction previously. In order to successfully deal with DTI challenges, we extended BPR by proposing: (i) the incorporation of target bias, (ii) a technique to handle new drugs and (iii) content alignment to take structural similarities of drugs and targets into account. RESULTS: Evaluation on five benchmark datasets shows that BRDTI outperforms several state-of-the-art approaches in terms of per-drug nDCG and AUC. BRDTI results w.r.t. nDCG are 0.929, 0.953, 0.948, 0.897 and 0.690 for G-Protein Coupled Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR), Enzymes (E) and Kinase (K) datasets respectively. Additionally, BRDTI significantly outperformed other methods (BLM-NII, WNN-GIP, NetLapRLS and CMF) w.r.t. nDCG in 17 out of 20 cases. Furthermore, BRDTI was also shown to be able to predict novel drug-target interactions not contained in the original datasets. The average recall at top-10 predicted targets for each drug was 0.762, 0.560, 1.000 and 0.404 for GPCR, IC, NR, and E datasets respectively. CONCLUSIONS: Based on the evaluation, we can conclude that BRDTI is an appropriate choice for researchers looking for an in silico DTI prediction technique to be used in drug-centric repositioning scenarios. BRDTI Software and supplementary materials are available online at www.ksi.mff.cuni.cz/∼peska/BRDTI.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033643
003      
CZ-PrNML
005      
20181023111823.0
007      
ta
008      
181008s2017 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cmpb.2017.09.003 $2 doi
035    __
$a (PubMed)29054256
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Peska, Ladislav $u Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic; Brain Imaging Centre, Hungarian Academy of Sciences, Budapest, Hungary. Electronic address: peska@ksi.mff.cuni.cz.
245    10
$a Drug-target interaction prediction: A Bayesian ranking approach / $c L. Peska, K. Buza, J. Koller,
520    9_
$a BACKGROUND AND OBJECTIVE: In silico prediction of drug-target interactions (DTI) could provide valuable information and speed-up the process of drug repositioning - finding novel usage for existing drugs. In our work, we focus on machine learning algorithms supporting drug-centric repositioning approach, which aims to find novel usage for existing or abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects the needs of drug-centric repositioning research better than conventional drug-target prediction approaches. METHODS: We propose Bayesian Ranking Prediction of Drug-Target Interactions (BRDTI). The method is based on Bayesian Personalized Ranking matrix factorization (BPR) which has been shown to be an excellent approach for various preference learning tasks, however, it has not been used for DTI prediction previously. In order to successfully deal with DTI challenges, we extended BPR by proposing: (i) the incorporation of target bias, (ii) a technique to handle new drugs and (iii) content alignment to take structural similarities of drugs and targets into account. RESULTS: Evaluation on five benchmark datasets shows that BRDTI outperforms several state-of-the-art approaches in terms of per-drug nDCG and AUC. BRDTI results w.r.t. nDCG are 0.929, 0.953, 0.948, 0.897 and 0.690 for G-Protein Coupled Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR), Enzymes (E) and Kinase (K) datasets respectively. Additionally, BRDTI significantly outperformed other methods (BLM-NII, WNN-GIP, NetLapRLS and CMF) w.r.t. nDCG in 17 out of 20 cases. Furthermore, BRDTI was also shown to be able to predict novel drug-target interactions not contained in the original datasets. The average recall at top-10 predicted targets for each drug was 0.762, 0.560, 1.000 and 0.404 for GPCR, IC, NR, and E datasets respectively. CONCLUSIONS: Based on the evaluation, we can conclude that BRDTI is an appropriate choice for researchers looking for an in silico DTI prediction technique to be used in drug-centric repositioning scenarios. BRDTI Software and supplementary materials are available online at www.ksi.mff.cuni.cz/∼peska/BRDTI.
650    _2
$a algoritmy $7 D000465
650    12
$a Bayesova věta $7 D001499
650    _2
$a datové soubory jako téma $7 D066264
650    _2
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a lidé $7 D006801
650    _2
$a strojové učení $7 D000069550
650    12
$a farmakologie $7 D010600
655    _2
$a časopisecké články $7 D016428
700    1_
$a Buza, Krisztian $u Brain Imaging Centre, Hungarian Academy of Sciences, Budapest, Hungary; Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
700    1_
$a Koller, Júlia $u Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary.
773    0_
$w MED00001214 $t Computer methods and programs in biomedicine $x 1872-7565 $g Roč. 152, č. - (2017), s. 15-21
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29054256 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181023112330 $b ABA008
999    __
$a ok $b bmc $g 1340957 $s 1030637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 152 $c - $d 15-21 $e 20170908 $i 1872-7565 $m Computer methods and programs in biomedicine $n Comput Methods Programs Biomed $x MED00001214
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...